Review of Global Glaucoma Clinical Trials in the Second Half of 2021 –

DUBLIN–(BUSINESS WIRE)–Clinical trial “Glaucoma – Global Clinical Trials Review, H2, 2021” has been added to from offer.

This report provides an overview of the glaucoma clinical trial scenario. This report provides front-line data from clinical trials in glaucoma. The report includes an overview of the number of trials and their average enrollment in major countries conducted across the world. The report offers disease-specific clinical trial coverage by region, country (G7 and E7), phase, trial status, endpoint status and sponsor type.

The report also provides leading drugs for ongoing trials (based on the number of ongoing trials). The publisher’s clinical trial reports are generated using the publisher’s proprietary database – Pharma – Clinical Trials Database. Clinical trials are collated from over 80 different clinical trial registries, conferences, reviews, news, and more. worldwide. The clinical trials database is periodically updated through a dynamic process.

The report enhances decision-making capabilities and helps in creating effective counter-strategies to gain competitive advantage.


  • The report provides an overview of the global clinical trials landscape

  • The report provides high-level clinical trial data by region, country (G7 and E7), trial status, trial phase, sponsor type and endpoint status

  • The report reviews the main companies involved and lists all trials (trial title, phase and status) relating to the company

  • The report provides all incomplete trials (completed, suspended and withdrawn) with the reason for the incompleteness

  • Report shows enrollment trends over the past five years

  • The report provides the latest news from the past three months

Reasons to buy

  • Helps formulate key business strategies for investing

  • Helps identify important locations for conducting clinical trials, saving time and money

  • Provides high-level analysis of the global clinical trials market that helps identify key business opportunities

  • Helps understand the number of trials and enrollment trends by country in the global therapeutics market

  • Helps interpret clinical trial success rates by providing a comparative scenario of completed and incomplete trials (completed, suspended or withdrawn)

  • Facilitates the evaluation of clinical trials of the indication at global, regional and national level

Companies cited

  • Alcon inc.

  • AbbVie Inc

  • Santen Pharmaceutical Co Ltd

  • Pfizer Inc.

  • Aerie Pharmaceuticals Inc.

  • Viatris inc.

  • Merck & Co Inc.

  • Kowa Co Ltd

  • Novartis AG

  • Bausch Health Companies Inc.

For more information on this clinical trial report, visit

Comments are closed.